Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease

NCT07085195 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07085195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07085195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease
Lead sponsor
Ruijin Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 1, 2025
Completion date
December 30, 2025
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clozapine, gene therapy, parkinson disease (pd), safety and efficacy